| Species |
Human |
| Protein Construction |
CD42b/GP1BA (His17-Leu531)
Accession # P07359 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD42b/GP1BA, His, Human at 1μg/ml (100μl/well) on the plate can bind AntiCD42b Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
57.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 110-115 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Absence of the CD42 complex leads to the Bernard-Soulier syndrome (BSS), which is a bleeding disorder characterized by thrombocytopenia and giant platelets. So far, mutations have been found in the genes encoding CD42a, CD42b and CD42c in patients with BSS**. |
| Synonyms |
GP-Ib alpha; GPIb-alpha; GPIbA; GP1BA; BDPLT1; BDPLT3; BSS; CD42B; CD42b-alpha; DBPLT3; GP1B; VWDP; BP1BA; MGC34595 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
